Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.25
NUVA's Cash-to-Debt is ranked lower than
85% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. NUVA: 0.25 )
Ranked among companies with meaningful Cash-to-Debt only.
NUVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.01 Max: No Debt
Current: 0.25
Equity-to-Asset 0.44
NUVA's Equity-to-Asset is ranked lower than
71% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. NUVA: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
NUVA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.16  Med: 0.49 Max: 0.9
Current: 0.44
-0.16
0.9
Interest Coverage 3.05
NUVA's Interest Coverage is ranked lower than
90% of the 241 Companies
in the Global Medical Devices industry.

( Industry Median: 77.33 vs. NUVA: 3.05 )
Ranked among companies with meaningful Interest Coverage only.
NUVA' s Interest Coverage Range Over the Past 10 Years
Min: 0.65  Med: 2.32 Max: No Debt
Current: 3.05
Piotroski F-Score: 4
Altman Z-Score: 3.62
Beneish M-Score: -2.45
WACC vs ROIC
9.36%
5.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 12.84
NUVA's Operating Margin % is ranked higher than
77% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. NUVA: 12.84 )
Ranked among companies with meaningful Operating Margin % only.
NUVA' s Operating Margin % Range Over the Past 10 Years
Min: -15.73  Med: 3.95 Max: 17.15
Current: 12.84
-15.73
17.15
Net Margin % 3.29
NUVA's Net Margin % is ranked higher than
56% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. NUVA: 3.29 )
Ranked among companies with meaningful Net Margin % only.
NUVA' s Net Margin % Range Over the Past 10 Years
Min: -12.92  Med: 0.83 Max: 16.37
Current: 3.29
-12.92
16.37
ROE % 4.56
NUVA's ROE % is ranked higher than
55% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. NUVA: 4.56 )
Ranked among companies with meaningful ROE % only.
NUVA' s ROE % Range Over the Past 10 Years
Min: -15.05  Med: 1 Max: 21.43
Current: 4.56
-15.05
21.43
ROA % 2.06
NUVA's ROA % is ranked higher than
57% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.21 vs. NUVA: 2.06 )
Ranked among companies with meaningful ROA % only.
NUVA' s ROA % Range Over the Past 10 Years
Min: -7.72  Med: 0.47 Max: 10.76
Current: 2.06
-7.72
10.76
ROC (Joel Greenblatt) % 25.90
NUVA's ROC (Joel Greenblatt) % is ranked higher than
74% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. NUVA: 25.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NUVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -42.62  Med: 10.28 Max: 47.3
Current: 25.9
-42.62
47.3
3-Year Revenue Growth Rate 6.70
NUVA's 3-Year Revenue Growth Rate is ranked higher than
57% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. NUVA: 6.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NUVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -40.2  Med: 12.55 Max: 480.7
Current: 6.7
-40.2
480.7
3-Year EBITDA Growth Rate 21.60
NUVA's 3-Year EBITDA Growth Rate is ranked higher than
74% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. NUVA: 21.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NUVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -36.3 Max: 24.4
Current: 21.6
0
24.4
3-Year EPS without NRI Growth Rate 59.50
NUVA's 3-Year EPS without NRI Growth Rate is ranked higher than
88% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. NUVA: 59.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NUVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: -30.4 Max: 162.1
Current: 59.5
-66.3
162.1
GuruFocus has detected 4 Warning Signs with NuVasive Inc $NUVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NUVA's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NUVA Guru Trades in Q1 2016

Pioneer Investments 33,834 sh (New)
Paul Tudor Jones 21,787 sh (New)
Steven Cohen 674,900 sh (+206.91%)
RS Investment Management 1,031,723 sh (+36.98%)
Mario Gabelli 170,000 sh (+2.32%)
Ken Fisher 1,410,780 sh (+0.51%)
PRIMECAP Management 901,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 806,000 sh (unchged)
Joel Greenblatt Sold Out
John Paulson Sold Out
Jim Simons 260,200 sh (-9.21%)
» More
Q2 2016

NUVA Guru Trades in Q2 2016

Pioneer Investments 63,589 sh (+87.94%)
Jim Simons 319,188 sh (+22.67%)
Ken Fisher 1,412,861 sh (+0.15%)
Mario Gabelli 167,000 sh (-1.76%)
PRIMECAP Management 869,600 sh (-3.49%)
RS Investment Management 784,483 sh (-23.96%)
Steven Cohen 242,400 sh (-64.08%)
Paul Tudor Jones 3,712 sh (-82.96%)
Eaton Vance Worldwide Health Sciences Fund 344,200 sh (-57.30%)
» More
Q3 2016

NUVA Guru Trades in Q3 2016

Jana Partners 80,744 sh (New)
Paul Tudor Jones 5,600 sh (+50.86%)
Pioneer Investments 70,786 sh (+11.32%)
Ken Fisher 1,422,585 sh (+0.69%)
Steven Cohen Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
PRIMECAP Management 869,000 sh (-0.07%)
Mario Gabelli 165,000 sh (-1.20%)
Jim Simons 129,600 sh (-59.40%)
» More
Q4 2016

NUVA Guru Trades in Q4 2016

Andreas Halvorsen 695,707 sh (New)
Jana Partners 1,810,169 sh (+2141.86%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Mario Gabelli 162,500 sh (-1.52%)
Ken Fisher 1,398,259 sh (-1.71%)
PRIMECAP Management 853,900 sh (-1.74%)
Pioneer Investments 31,754 sh (-55.14%)
» More
» Details

Insider Trades

Latest Guru Trades with NUVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare: » details
Traded in other countries:NK8.Germany,
NuVasive Inc is a medical device company. The Company develops minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its currently-marketed product portfolio is focused on applications for spine fusion surgery.

NuVasive is a medical-device company focused on minimally invasive surgical products and integrated solutions for spine surgery. The firm's spine surgery products contribute the majority of revenue. Its key offering is the maximum access surgery minimally disruptive surgical platform, which minimizes soft-tissue disruption and contact with critical nerves and maximizes visualization during spine fusion surgery. NuVasive also develops biologics used to aid in the spinal fusion or bone-healing processes, such as a collagen-based synthetic bone substitute and synthetic bone-graft material. NuVasive generates the majority of its revenue in the United States.

Top Ranked Articles about NuVasive Inc

Insiders Load Up on NuVasive as Price Tumbles 3 company insiders collectively purchase 26,172 shares
Multiple insiders of NuVasive (NUVA) purchased a total of 26,172 insider shares this week. Read more...

Ratios

vs
industry
vs
history
PE Ratio 131.47
NUVA's PE Ratio is ranked lower than
93% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 26.64 vs. NUVA: 131.47 )
Ranked among companies with meaningful PE Ratio only.
NUVA' s PE Ratio Range Over the Past 10 Years
Min: 11.39  Med: 89.48 Max: 387.67
Current: 131.47
11.39
387.67
Forward PE Ratio 37.04
NUVA's Forward PE Ratio is ranked lower than
75% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 23.98 vs. NUVA: 37.04 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 131.47
NUVA's PE Ratio without NRI is ranked lower than
93% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 28.00 vs. NUVA: 131.47 )
Ranked among companies with meaningful PE Ratio without NRI only.
NUVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.39  Med: 89.48 Max: 387.67
Current: 131.47
11.39
387.67
PB Ratio 5.43
NUVA's PB Ratio is ranked lower than
73% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.37 vs. NUVA: 5.43 )
Ranked among companies with meaningful PB Ratio only.
NUVA' s PB Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.63 Max: 10.89
Current: 5.43
0.98
10.89
PS Ratio 4.14
NUVA's PS Ratio is ranked lower than
59% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. NUVA: 4.14 )
Ranked among companies with meaningful PS Ratio only.
NUVA' s PS Ratio Range Over the Past 10 Years
Min: 0.85  Med: 3.18 Max: 10.54
Current: 4.14
0.85
10.54
Price-to-Free-Cash-Flow 61.10
NUVA's Price-to-Free-Cash-Flow is ranked lower than
82% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 28.14 vs. NUVA: 61.10 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NUVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.97  Med: 50.06 Max: 670.85
Current: 61.1
6.97
670.85
Price-to-Operating-Cash-Flow 24.96
NUVA's Price-to-Operating-Cash-Flow is ranked lower than
60% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. NUVA: 24.96 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NUVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.76  Med: 18.62 Max: 365.19
Current: 24.96
4.76
365.19
EV-to-EBIT 40.57
NUVA's EV-to-EBIT is ranked lower than
74% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 22.27 vs. NUVA: 40.57 )
Ranked among companies with meaningful EV-to-EBIT only.
NUVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -166  Med: 24 Max: 559.6
Current: 40.57
-166
559.6
EV-to-EBITDA 20.52
NUVA's EV-to-EBITDA is ranked lower than
62% of the 238 Companies
in the Global Medical Devices industry.

( Industry Median: 16.71 vs. NUVA: 20.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
NUVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -320.9  Med: 15.5 Max: 4339.7
Current: 20.52
-320.9
4339.7
Shiller PE Ratio 879.46
NUVA's Shiller PE Ratio is ranked lower than
96% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 53.11 vs. NUVA: 879.46 )
Ranked among companies with meaningful Shiller PE Ratio only.
NUVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 705.56  Med: 832.49 Max: 963.14
Current: 879.46
705.56
963.14
Current Ratio 2.37
NUVA's Current Ratio is ranked higher than
52% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. NUVA: 2.37 )
Ranked among companies with meaningful Current Ratio only.
NUVA' s Current Ratio Range Over the Past 10 Years
Min: 1.7  Med: 3.81 Max: 8.37
Current: 2.37
1.7
8.37
Quick Ratio 1.51
NUVA's Quick Ratio is ranked lower than
54% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. NUVA: 1.51 )
Ranked among companies with meaningful Quick Ratio only.
NUVA' s Quick Ratio Range Over the Past 10 Years
Min: 1.25  Med: 2.79 Max: 7.36
Current: 1.51
1.25
7.36
Days Inventory 301.55
NUVA's Days Inventory is ranked lower than
85% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 124.59 vs. NUVA: 301.55 )
Ranked among companies with meaningful Days Inventory only.
NUVA' s Days Inventory Range Over the Past 10 Years
Min: 266.24  Med: 334.46 Max: 491.78
Current: 301.55
266.24
491.78
Days Sales Outstanding 65.10
NUVA's Days Sales Outstanding is ranked higher than
54% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 67.79 vs. NUVA: 65.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
NUVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.35  Med: 58.06 Max: 75.34
Current: 65.1
52.35
75.34
Days Payable 13.87
NUVA's Days Payable is ranked lower than
92% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. NUVA: 13.87 )
Ranked among companies with meaningful Days Payable only.
NUVA' s Days Payable Range Over the Past 10 Years
Min: 12.75  Med: 27.32 Max: 63.36
Current: 13.87
12.75
63.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.90
NUVA's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. NUVA: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NUVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -215.4  Med: -5 Max: -3.8
Current: -3.9
-215.4
-3.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 4.34
NUVA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
76% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. NUVA: 4.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NUVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.2  Med: 2.51 Max: 18.72
Current: 4.34
1.2
18.72
Price-to-Median-PS-Value 1.30
NUVA's Price-to-Median-PS-Value is ranked lower than
64% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. NUVA: 1.30 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NUVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.04 Max: 2.79
Current: 1.3
0.3
2.79
Earnings Yield (Greenblatt) % 2.46
NUVA's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. NUVA: 2.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NUVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 2.4 Max: 6.8
Current: 2.46
0.2
6.8

More Statistics

Revenue (TTM) (Mil) $962.1
EPS (TTM) $ 0.57
Beta1.01
Short Percentage of Float9.22%
52-Week Range $45.35 - 76.31
Shares Outstanding (Mil)50.60

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,068 1,157 1,244
EPS ($) 2.02 2.46 2.81
EPS without NRI ($) 2.02 2.46 2.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
19.10%
Dividends per Share ($)
» More Articles for NUVA

Headlines

Articles On GuruFocus.com
Jana Partners' Largest 4th-Quarter Buys Mar 01 2017 
Insiders Load Up on NuVasive as Price Tumbles Nov 03 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 
Most-Bought Small Cap Stocks During 4th Quarter Mar 28 2016 
Weekly CEO Buys Highlight: BRKR, GAIN, LUB, NUVA, FGP Jun 21 2015 
Weekly CEO Buys Highlight: TPC, GBDC, NUVA, TEGP, JOY Jun 14 2015 
Weekly CEO Buys Highlight: TPC, NUVA, PHII, GBDC, ARO Jun 10 2015 
Weekly CEO Buys Highlight: NUVA, HK, BKFS, PODD, CLF Jun 02 2015 
Guru Fisher Cuts NUVA - Medical Insurance Resists NuVasive Procedure Apr 11 2013 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 2,015 Shares Jan 25 2011 

More From Other Websites
New Evidence-Based Recommendation Released From NICE (U.K.) For Lateral Interbody Fusion Mar 20 2017
Why Is NuVasive (NUVA) Up 3.1% Since the Last Earnings Report? Mar 15 2017
NuVasive to Participate in Investor Events in March 2017 Mar 02 2017
RBC Says These Top Health Care Stocks Could Be 2017 Takeover Candidates Mar 02 2017
Masimo's Stock Is a Great Buy Right Now Feb 28 2017
NUVASIVE INC Financials Feb 15 2017
Bets on financials, pharma power U.S. hedge funds' strong start to year Feb 14 2017
NuVasive, Inc. :NUVA-US: Earnings Analysis: 2016 By the Numbers : February 14, 2017 Feb 14 2017
NuVasive, Inc. :NUVA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 13, 2017 Feb 13 2017
NuVasive (NUVA) Beats Q4 Earnings, Revenues; Guides 2017 Feb 10 2017
Edited Transcript of NUVA earnings conference call or presentation 9-Feb-17 9:30pm GMT Feb 09 2017
NuVasive tops Street 4Q forecasts Feb 09 2017
NuVasive tops Street 4Q forecasts Feb 09 2017
NUVASIVE INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Feb 09 2017
NuVasive Reports Fourth Quarter And Full Year 2016 Financial Results Feb 09 2017
Manufacturer hiring 200+ at Dayton-area facility Feb 09 2017
Q4 2016 NuVasive Inc Earnings Release - After Market Close Feb 09 2017
Why NuVasive (NUVA) Might Surprise This Earnings Season Feb 07 2017
NuVasive To Present At Leerink Partners 6th Annual Global Healthcare Conference 2017 Feb 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)